From the literature
GHK-Cu: a copper-tripeptide found in human plasma, studied for collagen, skin, hair, and gene-expression research since 1973.
A hand-set reading of the peer-reviewed record — every collagen study, gene-expression map, and hair-follicle trial plated from the paper it came from.
What the GHK-Cu literature has measured
GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex) is a tripeptide-copper(II) chelate that occurs naturally in human plasma, saliva, and urine. At age 20–25, plasma concentration sits at approximately 200 ng/mL; by age 60–80 it has dropped to roughly 80 ng/mL [16]. That age-related decline coincides with the documented decrease in tissue regenerative capacity — and is what prompted Loren Pickart's initial isolation work in 1973, which has since generated more than fifty published studies.
The compound has been studied across collagen synthesis, wound healing, hair-follicle stimulation, anti-inflammatory signaling, lung-tissue protection, and broad gene-expression modulation. In 1988, Maquart et al. showed that GHK-Cu stimulated collagen synthesis in cultured human fibroblasts starting at concentrations as low as 10^-12 M, with maximum effect at 10^-9 M [1]. In 1993, subcutaneous implant models in rats demonstrated concentration-dependent increases in wound dry weight, collagen, and glycosaminoglycan content — with Type I and III collagen mRNA upregulation occurring without a corresponding TGF-beta mRNA increase [2].
By 2018, a computational Connectivity Map analysis attributed to GHK-Cu the modulation of over 4,000 human genes — roughly 31% of the protein-coding genome — with 59% of those genes upregulated and 41% suppressed [3]. The biological significance of that breadth in living tissue requires further study; the data derive from in vitro CMap profiling, not from direct gene expression measurements in humans.
Human clinical data exist primarily for topical application. Two 12-week randomized controlled trials showed statistically significant improvements in skin density, wrinkle depth, and skin laxity [7]. A 6-month RCT in 45 men with androgenetic alopecia produced statistically significant increases in hair count: 52.6 and 71.5 additional hairs per unit area in the two treatment groups, versus 9.6 in the placebo arm [11].
GHK-Cu is not FDA-approved for any therapeutic indication. Injectable forms have not been evaluated in published human pharmacokinetic or safety studies. The record reviewed on this site is an editorial digest of preclinical and early clinical findings — sourced to the papers they came from.
Four documented research areas
The published GHK-Cu literature organizes naturally into four areas that this site covers in depth.
Collagen and skin. Dermal fibroblast studies have confirmed collagen I and III gene upregulation at nanomolar concentrations [1]. Two small human RCTs documented anti-photoaging effects of topical GHK-Cu cream [7]. A comparative study found GHK-Cu produced superior procollagen synthesis (70% of subjects responding) versus vitamin C (50%) and retinoic acid (40%) in the same model [7]. See the GHK-Cu skin and collagen studies page for the full record.
Hair follicle research. GHK-Cu has been studied for hair follicle stimulation since the early 1990s [21]. The 2016 Lee et al. RCT is the strongest published human evidence: a daily topical scalp spray combining GHK with 5-aminolevulinic acid produced a statistically significant hair-count increase at 6 months with no adverse events [11]. See GHK-Cu hair loss research for this literature.
Wound healing and tissue repair. Pickart 2015 documents acceleration of wound closure across multiple species including rats, mice, rabbits, pigs, and dogs [4]. A 2025 hydrogel study achieved greater than 95% wound closure by day 12 in a murine infected wound model, compared to approximately 65% in controls [18]. See the GHK-Cu wound healing evidence on the research page.
Gene expression and organ protection. The 4,000-gene CMap analysis [3] and two 2023 intranasal mouse studies — one in aging mice, one in Alzheimer's transgenic mice — expand the research territory into neuroprotection [17][19]. Lung-protection studies in COPD and pulmonary fibrosis models add further scope [6][8][15]. All are preclinical.
What does GHK-Cu do?
GHK-Cu is a tripeptide-copper complex naturally occurring in human plasma that has been studied for roles in wound healing, collagen synthesis, anti-inflammatory signaling, and gene expression modulation in preclinical models. It delivers bioavailable copper(II) to cells, activating copper-dependent enzymes including superoxide dismutase (SOD2) and lysyl oxidase. It modulates TGF-beta and NF-kB signaling, suppresses inflammatory cytokines, and at nanomolar concentrations stimulates fibroblast proliferation and collagen gene transcription [1][3][4]. The compound has been the subject of peer-reviewed investigation for five decades.
How does GHK-Cu work?
GHK-Cu binds copper(II) ions with high affinity and is proposed to activate skin fibroblasts, upregulate SOD2 and collagen gene families, and modulate TGF-beta signaling pathways in tissue-repair rodent models [3][4]. Eight distinct pathways have been identified in published research: TGF-beta/Smad2/3 modulation (anti-fibrotic and pro-remodeling), NF-kB p65 suppression (anti-inflammatory), Nrf2 activation (antioxidant defense), copper-dependent lysyl oxidase activation (collagen crosslinking), VEGF upregulation (angiogenesis and hair follicle vascularization), integrin-beta1/p63 signaling (epidermal stem cell activation), ubiquitin proteasome system enhancement (cellular protein clearance), and SOD2 upregulation (mitochondrial antioxidant defense) [3][5][6][12]. Primary target cell types studied are dermal fibroblasts, epidermal keratinocytes, hair follicle dermal papilla cells, lung fibroblasts, and neuronal cells.
What does the evidence say about GHK-Cu and aging?
Preclinical data support GHK-Cu's role in skin repair and gene expression modulation [1][2][3]. The most direct human evidence: two small RCTs of topical application showed anti-photoaging effects in 71 and 41 women respectively, with GHK-Cu cream producing statistically significant improvements in skin density, wrinkle depth, and laxity [7]. The injectable form lacks robust human efficacy trials; no human pharmacokinetic data have been published. The age-related plasma decline from ~200 ng/mL to ~80 ng/mL [16] is the physiological correlate that motivates the anti-aging hypothesis — but correlation does not establish that external supplementation restores regenerative capacity in humans.
For frequently asked questions about GHK-Cu, see the FAQ page.